Phase II clinical trial of combination chemotherapy with dexamethasone for lymphoma in dogs.
Dogs with histologically confirmed lymphoma were treated with a 14-week induction chemotherapy protocol that included dexamethasone. A phase II clinical trial was done using a standard two-stage design. Complete remission occurred in 21 (88%) dogs, with a median initial progression-free interval of 186 days. Toxicity was mild and self-limiting in the majority of dogs.
Greenberg
Chelsea B
CB
Department of Veterinary Clinical Sciences, Purdue University, 625 Harrison Street, West Lafayette, Indiana 47907, USA.
Boria
Pedro A
PA
Borgatti-Jeffreys
Antonella
A
Raskin
Rose E
RE
Lucroy
Michael D
MD
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016130:Immunophenotyping / Q000662:veterinary; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012074:Remission Induction; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone